Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 304-780-6 | CAS number: 94279-36-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 04 Jun - 23 Sep 2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 023
- Report date:
- 2023
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- adopted in 2016
- Deviations:
- yes
- Remarks:
- minor deviations related to weighing schedule, acclimatisation period length, and an extra vaginal smear from one animal (details were given under material and methods); no influence on study outcome
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 1,2,4-Benzenetricarboxylic acid, tri-C9-11-alkyl esters
- EC Number:
- 304-780-6
- EC Name:
- 1,2,4-Benzenetricarboxylic acid, tri-C9-11-alkyl esters
- Cas Number:
- 94279-36-4
- Molecular formula:
- C36H60O6 to C42H72O6
- IUPAC Name:
- tris(C9-11-alkyl) benzene-1,2,4-tricarboxylate
1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Envigo RMS B.V., Horst, Netherlands
- Females nulliparous and non-pregnant: yes
- Age at arrival: 7 - 8 weeks (males and females)
- Weight at arrival: 175 - 207 g (males); 144 - 190 g (females)
- Fasting period before study: no
- Housing: From arrival to pairing, animals were housed up to 5 of one sex to a cage, in polysulfone solid bottomed cages measuring 59.5 × 38 × 20 cm (Tecniplast Gazzada S.a.r.l., Buguggiate, Varese, Italy). Nesting material was provided inside suitable bedding bags and changed at least twice a week. During mating, animals were housed one male to one female in clear polysulfone cages measuring 42.5 × 26.6 × 18.5 cm with a stainless steel mesh lid and floor (Tecniplast Gazzada S.a.r.l., Buguggiate, Varese, Italy). Each cage tray held absorbent material which was inspected and changed daily. After mating, male were housed as before mating, whereas the females were transferred to individual solid bottomed cages for the gestation period, birth and lactation (measuring 42.5 × 26.6 × 18.5 cm).
- Diet: A commercially available laboratory rodent diet (4 RF 21, Mucedola S.r.l., Settimo Milanese (MI), Italy) was offered ad libitum throughout the study.
- Water: Drinking water was supplied ad libitum to each cage via water bottles.
- Acclimation period: An acclimatisation period of 32 days was allowed before the start of treatment, during which time the health status of the animals was assessed by thorough observations. An acclimatisation period of 32 days was allowed before the start of treatment instead of approximately 3 weeks, as indicated in the Study Protocol.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2 °C
- Humidity (%): 55 ± 15%
- Air changes (per hr): 15 - 20
- Photoperiod (hrs dark / hrs light): 12 / 12
IN-LIFE DATES: 04 Jun - 16 Aug 2021
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The suspensions of the test item in corn oil was prepared using the following procedure:
1. the required amount of test item was weighed;
2. the required amount of vehicle was added;
3. the resulting mixture was left under magnetic stirring, at room temperature, for at least 30 min prior to dosing or analysis.
Dose volumes were adjusted once per week for each animal according to the last recorded body weight. During the gestation and lactation periods, dose volumes were calculated according to the last recorded body weight.
VEHICLE
- Justification for use and choice of vehicle (if other than water): Not specified
- Concentration in vehicle: The preparations were made weekly at concentrations of 25, 75 and 250 mg/mL based on stability data. Concentrations were calculated and expressed in terms of test item as supplied.
- Amount of vehicle (if gavage): The test item was administered orally by gavage at a dose volume of 4 mL/kg bw - Details on mating procedure:
- - M/F ratio per cage: 1/1 (with the exception of one male of Group 1 (control) paired with two females, because of the death of one control male)
- Length of cohabitation: overnight or up to 14 days
- Positive identification of copulation: sperm identification, vaginal plug in situ or copulation plugs found in the cage tray
The female was paired with the same male until positive identification occurred or 14 days had elapsed.
- After successful mating each pregnant female was caged (how): individually
A parturition check was performed from Day 20 to Day 25 post coitum. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analytical method was previously validated in the concentration range from 25 - 250 mg/mL. Linearity, accuracy and precision were within the limits stated in the validation protocol (r > 0.99; accuracy 85 - 115%; precision CV < 10%).
Samples of the formulations prepared in Weeks 1 and during the last week of treatment were analysed to check the homogeneity and concentration. Results of the analyses were within the acceptability limits stated in the laboratory SOPs for suspensions (85 - 115% for concentration and CV < 10% for homogeneity). - Duration of treatment / exposure:
- Males
Animals were dosed for 2 consecutive weeks prior to pairing, through the pairing period and thereafter until the day before necropsy, for a total of 32 days of treatment.
Females
Animals were dosed for 2 consecutive weeks prior to pairing and thereafter during pairing, post coitum and post partum periods until Day 13 post partum or the day before sacrifice (for a total of 51 to 57 days of treatment). - Frequency of treatment:
- daily, 7 days/week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels have been selected in consultation with the Sponsor based on information from a preliminary non-GLP study.
- Fasting period before blood sampling for clinical biochemistry: no - Positive control:
- No
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Once before commencement of treatment and at least once daily (animals were checked for mortality early in each working day and also in the afternoon).
Observations were performed at the same time interval each day, the interval was selected taking into consideration the presence of post-dose reactions.
From the beginning of the study up to Day 3 of the pre-mating phase, three sessions of clinical observations were scheduled: 0.5 - 1 h post-dose, 2 - 2.5 h post-dose and 4 - 4.5 h post-dose. From Day 4 up to the end of the study, the animals were observed for clinical signs at approximately 2 - 2.5 h after the treatment.
All observations were recorded for individual animals.
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: Males were weighed at allocation, then weekly from the start of dosing to termination.
Females were weighed at allocation, then weekly from the start of dosing to positive identification of mating and on Days 0, 7, 14 and 20 post coitum. Dams were also weighed on Days 1, 4, 7, 13 post partum and just before to necropsy.
- Animals were weighed on allocation and weekly from the start of treatment instead of weekly from allocation, as indicated in the Study Protocol.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption: The weight of food consumed by each cage of males and females was recorded weekly during the pre-mating period starting from the beginning of treatment up to mating. Individual food consumption for mated females was measured on Days 7, 14 and 20 post coitum starting from Day 0 post coitum and on Days 7 and 13 post partum starting from Day 1 post partum.
WATER CONSUMPTION AND COMPOUND INTAKE: No
OTHER: The day before sacrifice, blood samples (1.1 mL) for thyroid hormone determination were collected from all parental males under isoflurane anaesthesia from the retro-orbital sinus. - Oestrous cyclicity (parental animals):
- The assessment of oestrus cycles, by vaginal smears, was performed once daily in the morning in stock females and in allocated females for 2 weeks before the start of dosing.
From Day 1 of dosing up to positive identification of mating vaginal smears were taken in the morning to determine the following:
1. anomalies of the oestrus cycle
2. the pre-coital interval (i.e., the number of nights paired prior to the detection of mating)
Vaginal smears were also taken from all females, before despatch to necropsy and the oestrus cycle phase recorded.
Due to an oversight, in one control female animal the vaginal smear was also taken on Day 12 of the post partum period (not only before the despatch to necropsy).
Data from vaginal smears performed on stock females were not tabulated in this report, but archived with all raw data. - Sperm parameters (parental animals):
- Parameters examined in male parental generations: testis weight, epididymis weight
- Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: yes
- If yes, maximum of 8 pups/litter (4/sex/litter; partial adjustment (e.g. 5 males and 3 females) was acceptable); excess pups were eliminated by random selection; no pups were eliminated when litter size dropped below the culling target of 8 pups/litter
PARAMETERS EXAMINED
The following parameters were examined in F1 offspring: number and sex of pups, live births, postnatal mortality, presence of gross anomalies, weight gain, physical or behavioural abnormalities, anogenital distance (AGD), presence of nipples/areolae in male pups.
GROSS EXAMINATION OF DEAD PUPS: yes, for external and internal abnormalities; possible cause of death was determined for pups born or found dead
ASSESSMENT OF DEVELOPMENTAL NEUROTOXICITY: no
ASSESSMENT OF DEVELOPMENTAL IMMUNOTOXICITY: no - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: The males were killed on Day 19 of the mating phase after 32 days of treatment period.
- Maternal animals: The dams with live pups were killed on Day 14 post partum.
GROSS NECROPSY
- Gross necropsy consisted of external (surface and orifices) and internal examination.
- As a part of the necropsy procedure, blood samples (1.1 mL) for thyroid hormone determination were withdrawn from the abdominal vena cava of females under isoflurane anaesthesia.
All females were examined also for the following:
– number of visible implantation sites (pregnant animals)
– number of corpora lutea (pregnant animals)
HISTOPATHOLOGY / ORGAN WEIGHTS
- The following tissues were prepared for microscopic examination: adrenal glands, clitoral gland, epididymides, kidneys, liver, mammary gland - females, mammary gland - males, ovaries with oviducts, seminal vesicles with coagulating glands, testes, thyroid, uterus - cervix, vagina; morphological evaluation of the seminiferous epithelium (staging of spermatogenic cycle) was performed
- The following tissues were weighed: adrenal glands, epididymides, kidneys, liver, ovaries with oviducts, prostate gland (dorsolateral and ventral), seminal vesicles with coagulating glands, spleen, testes, thymus (where present), thyroid, uterus - cervix
The examination was restricted to:
- all males and females in the control and high dose groups killed at term
- male of the control group sacrificed during the treatment period
- all abnormalities in all groups - Postmortem examinations (offspring):
- SACRIFICE
- Culled pups were sacrificed on Day 4 post partum. All live pups were sacrificed on Day 14 post partum.
GROSS NECROPSY
- All pups found dead in the cage were examined for external and internal abnormalities.
- All culled pups sacrificed on Day 4 post partum were subjected to an external examination. Sex was determined by internal gonads inspection.
- All live pups sacrificed on Day 14 post partum were killed and examined for external abnormalities and sex confirmation by gonadal inspection.
- No nipples/areolae from male pups were retained since no nipples were found at Day 13 post partum.
HISTOPATHOLOGY / ORGAN WEIGHTS
- Thyroids were weighed from one male and one female pup selected for blood collection for hormone determination. For one dam, the thyroids were weighed from two different female pups because of the absence of male pups. - Statistics:
- Group mean values, where possible, were calculated for all parameters. Data from females which did not mate, non-pregnant and with total litter loss were excluded from group mean.
Standard deviations were calculated as appropriate. For continuous variables, e.g. body weight, food consumption and organ weights, the significance of the differences amongst group means was assessed by Dunnett’s test or a modified t test, depending on the homogeneity of data.
Statistical analysis of histopathological findings was carried out by means of the nonparametric Kolmogorov Smirnov test.
The non-parametric Kruskal-Wallis analysis of variance (non-continuous variables) was used for the other parameters. Intergroup differences between the control and treated groups were assessed by the non-parametric version of the Williams test. The criterion for statistical significance was p < 0.05. The mean values, standard deviations and statistical analysis were calculated from actual values in the computer without rounding off. - Reproductive indices:
- Males
Copulation index (%) = (no. of males with confirmed mating / no. of males cohabitated) x 100
Fertility index (%) = (no. of males which induced pregnancy / no. of males cohabitated) x 100
Females
Copulation index (%) = (no. of females with confirmed mating / no. of females cohabitated) x 100
Fertility index (%) = (no. of pregnant females / no. of females cohabitated) x 100
Males and females
Coital interval = The number of nights paired prior to the detection of mating
Gestation length = The time between the day of successful mating (Day post coitum) and the day of birth when parturition was defined complete (Day 0 post partum). - Offspring viability indices:
- Pre-implantation loss (%) = ((no. of corpora lutea - no. of implantations) / no. of corpora lutea) x 100
Pre-natal loss (%) = ((no. of visible implantations - live litter size at birth) / no. of visible implantations) x 100
Pup loss at Day 0 post partum (%) = ((total litter size - live litter size) / total litter size) x 100
Postnatal loss on Day 4 post partum (before culling) (%) = ((live litter size at birth - live litter size at Day 4, before culling) / live litter size at birth) x 100
Postnatal loss on Day 13 post partum (after culling) (%) = ((live litter size on Day 4, after culling - live litter size on Day 13) / live litter size on Day 4, after culling) x 100
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Males
No clinical signs were observed in all treated males before pairing and during the mating phase.
Females
No clinical signs were observed in all treated females before and during mating, during the gestation period and throughout the post partum phase. - Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One case of unscheduled death occurred in the control group: one male animal was sacrificed for humane reasons on Day 7 of the pre-mating phase.
At post mortem examination, the gavage catheter or cannula was present in the oesophagus. Error at gavage procedure was considered to represent the cause of death. - Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Body weight of treated and control animals was comparable throughout the entire study.
Mean body weight gain of mid-dose males was found statistically significantly lower than controls on Day 15 of the mating phase. A statistically significant decrease in body weight gain was also observed for females of the low and mid-dose groups on Day 8 of the premating phase. Being isolated events and without a dose-related trend, these cases were not considered to be treatment-related. - Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related changes were seen in food consumption during the whole duration of the study.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Thyroid hormones
No changes were recorded in thyroid hormones of parental male and female animals at the end of the treatment period. - Endocrine findings:
- not specified
- Description (incidence and severity):
- The following ED-related parameters were investigated in the study:
- thyroid hormones
- accessory sex organ weight and histopathology
- anogenital distance
- coagulating gland weight
- sex organ weight and histopathology
- oestrus cyclicity
- genital abnormalities
- nipple development
- thyroid weight and histopathology
- vaginal smears
- fertility
- fetal development
- gestation length
- litter size
- litter viability
- litter / pup weight
- number of implantations, corpora lutea
- number of live births
- pre-implantation / pre-natal loss
- reproduction
- sex ratio
For details, please refer to the respective result fields and the endpoint summary. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related changes were noted in the sex organs/tissues of males and females at 1000 mg/kg bw/day, when compared to controls.
There were no treatment-related microscopic observations in the testes examined with PAS special stain.
The sporadic microscopic observations in control and/or treated males were consistent with those known to occur spontaneously in untreated SD rats of the same age and were considered incidental and unrelated to treatment. - Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Description (incidence and severity):
- The oestrus cyclicity of the treated females monitored during the pre-mating period, for a total of 14 days, was not affected by treatment. The mean number of oestrus cycles observed in treated animals and controls was 3 cycles.
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- Three mid-dose females and two high dose females were sacrificed on Days 26 and 27 post coitum and found not pregnant.
One high dose female showed total litter loss on Day 3 post partum and therefore was sacrificed on Day 4 post partum.
Two control females did not show evidence of copulation after 2 weeks of mating. One of the two gave birth at the end of the gestation phase. One female was sacrificed on Day 43 of the mating phase and found not pregnant.
The number of dams with live pups on Day 14 post partum was: 9 in the control, 10 in the low dose (100 mg/kg/day), 7 in mid (300 mg/kg/day) and high dose (1000 mg/kg/day) groups. See 'Any other information on results incl. tables', Table 1.
The number of copulatory plugs (mean value) found in the cage was 3 each in control and in the treated groups.
Copulatory and fertility indices were considered to be unaffected by the administration of the test item.
Males and females
The copulatory indices were 90% for controls and 100% in all treated groups of both sexes.
The fertility indices were 88.9% in males and 90% in females for controls and for both sexes, 100% in low dose animals, 70 and 80% in mid and high dose animals, respectively.
Animals, both in control and treated groups, mated after 2/3 days (mean pre-coital interval) of cohabitation.
The number of implantations, live litter size, pre-implantation and pre-natal loss did not show treatment-related differences. Mean gestation period was comparable between control and treated animals. All dams give birth between Days 22 and 23 post coitum.
Effect levels (P0)
open allclose all
- Dose descriptor:
- NOAEL
- Remarks:
- general toxicity
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects were observed up to the highest dose
- Dose descriptor:
- NOAEL
- Remarks:
- reproductive toxicity
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects were observed up to the highest dose
Target system / organ toxicity (P0)
- Critical effects observed:
- no
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Some clinical signs, such as small size, coldness to touch, apparently no food intake and difficulty in breathing, were observed in some pups of treated groups. These findings were mostly noted in litters from individual dam (2 dams in Group 2, 1 dam in Group 3, and 2 dams in Group 4). Most of pups did not recover from these signs and were found dead or missing.
In addition, an increase incidence of found dead pups was recorded in treated groups. This trend correlates with the slight increase in pup loss percentage observed in the high dose group.
Since clinical signs, losses and/or missing pups were mainly noted in individual animals, the correlation to treatment was not clear. See 'Any other information on results incl. tables', Table 2 and 3. - Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- Total litter size and live litter size at birth and on Days 1, 4 and 13 post partum were comparable between groups. The value of post-natal loss was observed to be greater for the high dose group on Day 4 post partum, but without statistical significance. This occurrence was mainly due to one dam which lost its litter on Day 3 post partum.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No differences in litter weight and mean pup weight were observed among treated and control animal, from birth up to Day 13 post partum.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Thyroid hormones
Pups – Day 14 post partum
No changes were recorded in thyroid hormones of male and female pups. - Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Anogenital distance (AGD):
- no effects observed
- Description (incidence and severity):
- Anogenital distance was comparable between control and treated groups.
- Nipple retention in male pups:
- not examined
- Description (incidence and severity):
- Not examined as no nipples were found on Day 13 post partum.
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No differences were observed at statistical analysis in the thyroid weight in treated groups, when compared to controls.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No findings were observed in decedent pups, nor in pups sacrificed on Days 4 and 14 post partum.
- Histopathological findings:
- not examined
- Other effects:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Sex ratios at birth, on Days 4 and 14 post partum showed a decrease in male pups percentage of the high dose group, compared to controls, without statistical significance. This difference was not considered to be treatment-related.
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not examined
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not examined
Effect levels (F1)
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects were observed up to the highest dose
Target system / organ toxicity (F1)
- Critical effects observed:
- no
Overall reproductive toxicity
- Reproductive effects observed:
- no
Any other information on results incl. tables
Table 1: Summary of reproduction data – Group data
Observations |
Dose levels (mg/kg bw/day) |
|||
0 |
100 |
300 |
1000 |
|
No. Dams with positive identification of mating |
9 |
10 |
10 |
10 |
Oestrus cycle (mean number) |
3 |
3 |
3 |
3 |
No. Dams That Conceived |
9 |
10 |
7 |
8 |
Percent Dams Conceived/total |
90.0 |
100.0 |
70.0 |
80.0 |
Positive identification of mating (1-5 days) |
8 |
10 |
10 |
9 |
Positive identification of mating (6-14 days) |
0 |
0 |
0 |
1 |
No. Dams Died During Study |
0 |
0 |
0 |
0 |
No. Dams with Resorptions only |
0 |
0 |
0 |
0 |
No. of Litters |
9 |
10 |
7 |
8 |
Total No. Corpora Lutea |
135 |
145 |
99 |
115 |
Mean No. Corpora Lutea/Pregnancy |
15.0 |
14.5 |
14.1 |
14.4 |
Total No. Implantation |
135 |
145 |
99 |
115 |
Mean No. Implants/Pregnancy |
15.0 |
14.5 |
14.1 |
14.4 |
Total No. Resorptions |
0 |
0 |
0 |
0 |
Preimplantation Loss (%) |
0.0 |
0.0 |
0.0 |
0.0 |
Pre natal Loss (%) |
24.38 |
18.99 |
10.36 |
23.56 |
Table 2: Litter data at birth on Day 1 and on Day 4 post partum (before culling) of females with live pups at Day 1 post partum – Group mean data
Group |
|
At birth |
On Day 1 post partum |
On Day 4 post partum |
|||||||
Total litter size |
Live litter size |
Post natal loss (%) |
Live litter size |
Litter weight (g) |
Mean pup weight (g) |
Live litter size |
Post natal loss (%) |
Litter weight (g) |
Mean pup weight (g) |
||
1 |
Mean |
11.67 |
11.56 |
0.86 |
11.33 |
78.72 |
7.07 |
11.33 |
1.62 |
114.89 |
10.53 |
SD |
4.18 |
4.16 |
2.57 |
4.03 |
24.95 |
0.69 |
4.03 |
3.26 |
32.74 |
1.46 |
|
N |
9 |
9 |
9 |
9 |
9 |
9 |
9 |
9 |
9 |
9 |
|
2 |
Mean |
13.00 |
11.80 |
8.92 |
11.50 |
72.18 |
6.37 |
11.30 |
4.47 |
103.17 |
9.33 |
SD |
2.21 |
2.53 |
12.69 |
2.80 |
14.54 |
0.60 |
2.67 |
6.47 |
16.80 |
1.32 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
3 |
Mean |
13.43 |
12.71 |
5.09 |
12.29 |
81.54 |
6.70 |
12.29 |
3.33 |
118.01 |
9.77 |
SD |
2.64 |
2.69 |
9.21 |
2.69 |
13.05 |
0.59 |
2.69 |
5.76 |
16.82 |
1.21 |
|
N |
7 |
7 |
7 |
7 |
7 |
7 |
7 |
7 |
7 |
7 |
|
4 |
Mean |
13.00 |
11.25 |
13.25 |
10.50 |
70.23 |
6.59 |
10.25 |
17.86 |
106.26 |
9.43 |
SD |
3.55 |
4.80 |
25.27 |
5.83 |
39.27 |
1.20 |
6.27 |
36.43 |
40.60 |
1.96 |
|
N |
8 |
8 |
8 |
8 |
8 |
8 |
8 |
8 |
7 |
7 |
|
Statistical analysis: Kruskall Wallis test William’s test if group mean differences are different from control at p < 0.05 * = mean value of group is significantly different from control |
Table 3: Clinical signs of pups – Group incidence
Groups |
1 |
2 |
3 |
4 |
||||
Litters observed |
9 |
10 |
7 |
8 |
||||
|
Affected no. |
% |
Affected no. |
% |
Affected no. |
% |
Affected no. |
% |
Small/Smaller than others |
2 |
22.2 |
3 |
30.0 |
1 |
14.3 |
2 |
25.0 |
Cold/Cold to touch |
0 |
0.0 |
1 |
10.0 |
1 |
14.3 |
3 |
37.5 |
Apparently no food intake |
0 |
0.0 |
2 |
20.0 |
0 |
0.0 |
3 |
37.5 |
Difficulty in breathing |
0 |
0.0 |
0 |
0.0 |
1 |
14.3 |
0 |
0.0 |
Pale |
0 |
0.0 |
1 |
10.0 |
0 |
0.0 |
0 |
0.0 |
Applicant's summary and conclusion
- Conclusions:
- The test item had no effect on reproductive performance. The NOAEL was concluded to be >/= 1000 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
